The authors reply

New England Journal of Medicine

Volumn 372, Issue 17, 2015, Pages 1673-

  Francis, Prudence A ^a   Regan, Meredith M ^b   Fleming, Gini F ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b International Breast Cancer Study Group Statistical Center   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER THERAPY; CHEMOTHERAPY; HUMAN; LETTER; OVARIAN SUPPRESSION; OVARY FUNCTION; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; THERAPY EFFECT; BREAST NEOPLASMS; FEMALE;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN;

EID: 84928760916     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1502618     Document Type: Letter

References (2)

1. PA Francis MM Regan GF Fleming Adjuvant ovarian suppression in premenopausal breast cancer N Engl J Med 372 2015 436 446
2. A Goldhirsch EP Winer AS Coates Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 24 2013 2206 2223